{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:29:21Z","timestamp":1761863361569},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T00:00:00Z","timestamp":1415059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s12032-014-0308-x","type":"journal-article","created":{"date-parts":[[2014,11,3]],"date-time":"2014-11-03T17:00:28Z","timestamp":1415034028000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study"],"prefix":"10.1007","volume":"31","author":[{"given":"Klaus","family":"Pietzner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radoslav","family":"Chekerov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Marm\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Martinius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilke","family":"Friccius-Quecke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,4]]},"reference":[{"key":"308_CR1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdl499","volume":"18","author":"AA Ayantunde","year":"2007","unstructured":"Ayantunde AA, Parsons S. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18:945\u20139.","journal-title":"Ann Oncol"},{"key":"308_CR2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11864-008-0068-y","volume":"9","author":"M Chung","year":"2008","unstructured":"Chung M, Kozuch P. Treatment of malignant ascites. Curr Treat Options Oncol. 2008;9:215\u201333.","journal-title":"Curr Treat Options Oncol"},{"key":"308_CR3","first-page":"109","volume":"134","author":"J Tamsma","year":"2007","unstructured":"Tamsma J. The pathogenesis of malignant ascites. Cancer Treat Res. 2007;134:109\u201318.","journal-title":"Cancer Treat Res"},{"key":"308_CR4","first-page":"3353","volume":"29","author":"H Woopen","year":"2009","unstructured":"Woopen H, Sehouli J. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res. 2009;29:3353\u20139.","journal-title":"Anticancer Res"},{"key":"308_CR5","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3892\/or.2012.1913","volume":"28","author":"S Cui","year":"2012","unstructured":"Cui S, Ba M, Tang Y, Liu J, Wu Y, Wang B, Zhang X, Tang H, Zhong S. B ultrasound-guided hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites. Oncol Rep. 2012;28:1325\u201331.","journal-title":"Oncol Rep"},{"key":"308_CR6","first-page":"4625","volume":"31","author":"I Takeyoshi","year":"2011","unstructured":"Takeyoshi I, Makita F, Iwazaki S, Ishikawa H, Kakinuma S, Sato Y, Ohya T, Nakagami K, Tomizawa N, Izumi M, Kobayashi I, Tanahashi Y, Kobayashi J, Kamoshita N, Kawate S, Sunose Y, Sakamoto I, Yoshinari D, Yamada T, Okabe T. Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites. Anticancer Res. 2011;31:4625\u201330.","journal-title":"Anticancer Res"},{"key":"308_CR7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.21321","volume":"100","author":"M Valle","year":"2009","unstructured":"Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal preoperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. Surg Oncol. 2009;100:331\u20134.","journal-title":"Surg Oncol"},{"key":"308_CR8","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","volume":"198","author":"RA Adam","year":"2004","unstructured":"Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198:999\u20131011.","journal-title":"J Am Coll Surg"},{"key":"308_CR9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","volume":"42","author":"G Becker","year":"2006","unstructured":"Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42:589\u201397.","journal-title":"Eur J Cancer"},{"key":"308_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","volume":"18","author":"E Cavazzoni","year":"2013","unstructured":"Cavazzoni E, Bugiantella W, Graziosi L, Franceschini MS, Donini A. Malignant ascites: pathophysiology and treatment. Int J Clin Oncol. 2013;18:1\u20139.","journal-title":"Int J Clin Oncol"},{"key":"308_CR11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2010.07.016","volume":"79","author":"S Barni","year":"2011","unstructured":"Barni S, Cabiddu M, Ghilardi M, Petrelli F. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites. Crit Rev Oncol Hematol. 2011;79:144\u201353.","journal-title":"Crit Rev Oncol Hematol"},{"key":"308_CR12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ctrv.2010.03.001","volume":"36","author":"D Seimetz","year":"2010","unstructured":"Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010;36:458\u201367.","journal-title":"Cancer Treat Rev"},{"key":"308_CR13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.humpath.2003.08.026","volume":"35","author":"P Went","year":"2004","unstructured":"Went P, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S. Frequent EpCAM protein expression in human carcinomas. Hum Pathol. 2004;35:122\u20138.","journal-title":"Hum Pathol"},{"key":"308_CR14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.bjc.6602924","volume":"94","author":"P Went","year":"2006","unstructured":"Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, Kononen J, Simon R, Sauter G, Baeuerle PA. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006;94:128\u201335.","journal-title":"Br J Cancer"},{"key":"308_CR15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/jcp.2011.090274","volume":"64","author":"G Spizzo","year":"2011","unstructured":"Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, Mazzoleni G, Gastl G, Went P. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. Clin Pathol. 2011;64:415\u201320.","journal-title":"Clin Pathol"},{"key":"308_CR16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctrv.2011.04.002","volume":"38","author":"C Patriarca","year":"2012","unstructured":"Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev. 2012;38:68\u201375.","journal-title":"Cancer Treat Rev"},{"key":"308_CR17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s004280050393","volume":"435","author":"B Davidson","year":"1999","unstructured":"Davidson B, Risberg B, Kristensen G, Kvalheim G, Emilsen E, Bj\u00e5mer A, Berner A. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies: evaluation of five epithelial markers. Virchows Arch. 1999;435:43\u20139.","journal-title":"Virchows Arch"},{"key":"308_CR18","doi-asserted-by":"crossref","first-page":"6862","DOI":"10.1158\/1078-0432.CCR-05-0043","volume":"11","author":"K Passebosc-Faure","year":"2005","unstructured":"Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, P\u00e9rol M, Genin C. Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res. 2005;11:6862\u20137.","journal-title":"Clin Cancer Res"},{"key":"308_CR19","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1182\/blood.V98.8.2526","volume":"98","author":"P Ruf","year":"2001","unstructured":"Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001;98:2526\u201334.","journal-title":"Blood"},{"key":"308_CR20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bjc.6603881","volume":"97","author":"P Ruf","year":"2007","unstructured":"Ruf P, Gires O, J\u00e4ger M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer. 2007;97:315\u201321.","journal-title":"Br J Cancer"},{"key":"308_CR21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1054\/bjoc.2000.1237","volume":"83","author":"R Zeidler","year":"2000","unstructured":"Zeidler R, Mysliwietz J, Cs\u00e1nady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83:261\u20136.","journal-title":"Br J Cancer"},{"key":"308_CR22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/0008-5472.CAN-11-2235","volume":"72","author":"M J\u00e4ger","year":"2012","unstructured":"J\u00e4ger M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Str\u00f6hlein M, Theissen B, Heiss MM, Lindhofer H. Immunomonitoring results of a phase II\/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res. 2012;72:24\u201332.","journal-title":"Cancer Res"},{"key":"308_CR23","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4049\/jimmunol.163.3.1246","volume":"163","author":"R Zeidler","year":"1999","unstructured":"Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T-cells and accessory cells by a new class of intact bispecific antibody results in efficient tumour cell killing. J Immunol. 1999;163:1246\u201352.","journal-title":"J Immunol"},{"key":"308_CR24","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer. 2010;127:2209\u201321.","journal-title":"Int J Cancer"},{"key":"308_CR25","doi-asserted-by":"crossref","unstructured":"Sehouli J, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton Rigaud D, Lordick F. Catumaxomab versus catumaxomab plus prednisolone in patients with malignant ascites due to epithelial cancer: results from the CASIMAS study. Ann Oncol. 2012;23 (Suppl 9):ix539[Abstract 1683P].","DOI":"10.1016\/S0923-7534(20)34229-0"},{"key":"308_CR26","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/ijc.26258","volume":"130","author":"MG Ott","year":"2012","unstructured":"Ott MG, Marm\u00e9 F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II\/III study in patients with malignant ascites. Int J Cancer. 2012;130:2195\u2013203.","journal-title":"Int J Cancer"},{"key":"308_CR27","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s12032-011-9961-5","volume":"29","author":"K Pietzner","year":"2012","unstructured":"Pietzner K, J\u00e4ger M, Schoberth A, Oskay-\u00d6zcelik G, Kuhberg M, Lindhofer H, Sehouli J. First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report. Med Oncol. 2012;29:1391\u20136.","journal-title":"Med Oncol"},{"key":"308_CR28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group. EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"308_CR29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2012.11.013","volume":"128","author":"D Cella","year":"2013","unstructured":"Cella D, Neubauer N, Thomas J, Kutner J, Seiden MV. The FACIT-AI, a new tool for assessing symptoms associated with malignant ascites. Gynecol Oncol. 2013;128:187\u201390.","journal-title":"Gynecol Oncol"},{"key":"308_CR30","doi-asserted-by":"crossref","unstructured":"Ruf P, Foerster B, Jager M, Martinius H, Seimetz D, Lindhofer H. Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites. J Clin Oncol. 2011;29 (suppl: abstr 2575).","DOI":"10.1200\/jco.2011.29.15_suppl.2575"},{"key":"308_CR31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00262-002-0350-y","volume":"52","author":"GL DeNardo","year":"2003","unstructured":"DeNardo GL, Bradt BM, Mirick GR, DeNardo SJ. Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother. 2003;52:309\u201316.","journal-title":"Cancer Immunol Immunother"},{"key":"308_CR32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ijc.10562","volume":"101","author":"A Marm\u00e9","year":"2002","unstructured":"Marm\u00e9 A, Strauss G, Bastert G, Grischke EM, Moldenhauer G. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer. 2002;101:183\u20139.","journal-title":"Int J Cancer"},{"key":"308_CR33","first-page":"251","volume":"48","author":"GR Mirick","year":"2004","unstructured":"Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human antiglobulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging. 2004;48:251\u20137.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"308_CR34","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-006-0148-4","volume":"55","author":"I Azinovic","year":"2006","unstructured":"Azinovic I, DeNardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM, DeNardo SJ. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother. 2006;55:1451\u20138.","journal-title":"Cancer Immunol Immunother"},{"key":"308_CR35","first-page":"4013S","volume":"9","author":"GL DeNardo","year":"2003","unstructured":"DeNardo GL, Mirick GR, Kroger LA, Bradt BM, Lamborn KR, DeNardo SJ. Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Clin Cancer Res. 2003;9:4013S\u201321S.","journal-title":"Clin Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0308-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-014-0308-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0308-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T20:18:00Z","timestamp":1689625080000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-014-0308-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,4]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["308"],"URL":"https:\/\/doi.org\/10.1007\/s12032-014-0308-x","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,4]]},"article-number":"308"}}